Lipid-lowering therapies for the secondary prevention of cardiovascular disease in primary care

What percentage of global deaths are caused by cardiovascular disease?

Which of the following are non-modifiable risk factors for CVD? (More than one answer may be correct)

‘CVDPREVENT’ is a national primary care audit that uses GP data to assess the risk factors that may contribute to CVD.

Which of the following conditions are included in this audit? (More than one answer may be correct)

Which of the following lipid profiles would suggest an increased risk of CVD?

What does the National Institute for Health and Care Excellence (NICE) recommend as the LDL lipid target for the secondary prevention of CPD?

NICE recommends that individuals at risk of CVD should eat a cardioprotective diet. What percentage should fat intake be of a person’s total diet?

Which statin is associated with elevated levels of liver transaminases if used at high intensity?

Which of the following are risk factors for muscle symptoms when taking statins? (More than one answer may be correct)

Which of the following statements about ezetimibe are true? More than one answer may be correct.

Inclisiran is a small interfering RNA drug that targets expression of which gene?

Which lipid-lowering therapies are initiated in secondary care? More than one answer may be correct.

Alirocumab and evolocumab are both PCSK9 inhibitors. What other drug class do they belong to?

When would bempedoic acid be indicated?

Icosapent ethyl is indicated in those that are already on statins with triglycerides greater than 1.7mmol/L. From what natural source is icosapent ethyl derived?

A 40-year-old woman presents to you with a history of CVD and whose recent lipid tests showed non-HDL 3.2 mm/L and LDL2.4mm/L. Statins are contraindicated and bloods showed a raised serum urate level — what treatment could be considered?